Empagliflozin, a potent, selective inhibitor of sodium glucose cotransporter 2 (SGLT2), is an oral glucose-lowering agent widely used for the treatment of type 2 diabetes mellitus (DM) (13–15) (16), especially in patients with established cardiovascular disease (17) or heart failure or chronic kidney disease (CKD) (18) because of its favorable cardiorenal outcomes. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.